JP2018507210A - 小胞モノアミン輸送体２のジメトキシフェニル系阻害剤 - Google Patents

小胞モノアミン輸送体２のジメトキシフェニル系阻害剤 Download PDF

Info

Publication number
JP2018507210A
JP2018507210A JP2017543828A JP2017543828A JP2018507210A JP 2018507210 A JP2018507210 A JP 2018507210A JP 2017543828 A JP2017543828 A JP 2017543828A JP 2017543828 A JP2017543828 A JP 2017543828A JP 2018507210 A JP2018507210 A JP 2018507210A
Authority
JP
Japan
Prior art keywords
compound
deuterium
disease
dystonia
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017543828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507210A5 (cg-RX-API-DMAC7.html
Inventor
チャン，チェンジー
Original Assignee
オースペックス ファーマシューティカルズ インコーポレイテッド
オースペックス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オースペックス ファーマシューティカルズ インコーポレイテッド, オースペックス ファーマシューティカルズ インコーポレイテッド filed Critical オースペックス ファーマシューティカルズ インコーポレイテッド
Publication of JP2018507210A publication Critical patent/JP2018507210A/ja
Publication of JP2018507210A5 publication Critical patent/JP2018507210A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017543828A 2015-02-18 2016-02-17 小胞モノアミン輸送体２のジメトキシフェニル系阻害剤 Pending JP2018507210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117654P 2015-02-18 2015-02-18
US62/117,654 2015-02-18
PCT/US2016/018222 WO2016133989A1 (en) 2015-02-18 2016-02-17 Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2

Publications (2)

Publication Number Publication Date
JP2018507210A true JP2018507210A (ja) 2018-03-15
JP2018507210A5 JP2018507210A5 (cg-RX-API-DMAC7.html) 2019-03-22

Family

ID=56692737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543828A Pending JP2018507210A (ja) 2015-02-18 2016-02-17 小胞モノアミン輸送体２のジメトキシフェニル系阻害剤

Country Status (12)

Country Link
US (1) US10722479B2 (cg-RX-API-DMAC7.html)
EP (1) EP3258926A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018507210A (cg-RX-API-DMAC7.html)
AR (1) AR103728A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017017673A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976229A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791839A1 (cg-RX-API-DMAC7.html)
IL (1) IL253901A0 (cg-RX-API-DMAC7.html)
MA (1) MA41557A (cg-RX-API-DMAC7.html)
MX (1) MX2017010567A (cg-RX-API-DMAC7.html)
TW (1) TW201630871A (cg-RX-API-DMAC7.html)
WO (1) WO2016133989A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
JP2009538355A (ja) * 2006-05-26 2009-11-05 オースペックス・ファーマシューティカルズ・インコーポレイテッド ジューテリウム化アミノグリシジル化合物
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
JP2012503010A (ja) * 2008-09-18 2012-02-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 小胞モノアミン輸送体２のベンゾキノリン阻害剤
JP2013527237A (ja) * 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系ｖｍａｔ２阻害剤
US20140341994A1 (en) * 2012-09-18 2014-11-20 Auspex Pharmaceuticals, Inc. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014202646A1 (en) * 2013-06-19 2014-12-24 Som Innovation Biotech, S.L. Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211815A (en) 1984-05-15 1988-11-29 Warner Lambert Co Preparation of 1-((3,4-dimethoxyphenethyl)amino)-3- (3-tolyloxy)-2-propanol

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538355A (ja) * 2006-05-26 2009-11-05 オースペックス・ファーマシューティカルズ・インコーポレイテッド ジューテリウム化アミノグリシジル化合物
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
JP2012503010A (ja) * 2008-09-18 2012-02-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 小胞モノアミン輸送体２のベンゾキノリン阻害剤
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
JP2013527237A (ja) * 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系ｖｍａｔ２阻害剤
US20140341994A1 (en) * 2012-09-18 2014-11-20 Auspex Pharmaceuticals, Inc. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014202646A1 (en) * 2013-06-19 2014-12-24 Som Innovation Biotech, S.L. Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAS登録番号 1068706-80-8, REGISTRY（STN）[ONLINE], JPN7019003949, ISSN: 0004168547 *
CAS登録番号 1185097-33-9, REGISTRY（STN）[ONLINE], JPN7019003948, ISSN: 0004168546 *
CAS登録番号 1185194-18-6, REGISTRY（STN）[ONLINE], JPN7019003947, ISSN: 0004168545 *
CAS登録番号 1188265-52-2, REGISTRY（STN）[ONLINE], JPN7019003946, ISSN: 0004168544 *
CAS登録番号 1261393-48-9, REGISTRY（STN）[ONLINE], JPN7019003944, ISSN: 0004168543 *
CAS登録番号 1261395-04-3, REGISTRY（STN）[ONLINE], JPN7019003943, ISSN: 0004168542 *
CAS登録番号 1309283-11-1, REGISTRY（STN）[ONLINE], JPN7019003942, ISSN: 0004168541 *
CAS登録番号 1329838-45-0, REGISTRY（STN）[ONLINE], JPN7019003940, ISSN: 0004168540 *
CAS登録番号 1398065-71-8, REGISTRY（STN）[ONLINE], JPN7019003939, ISSN: 0004168539 *
PONY YU, RENYUAN; HESK, DAVID; RIVERA, NELO; PELCZER, ISTVAN; CHIRIK, PAUL J.: "Iron-catalysed tritiation of pharmaceuticals", NATURE, vol. 529(7585), JPN6019047759, 2016, pages 195 - 199, ISSN: 0004168538 *

Also Published As

Publication number Publication date
EP3258926A4 (en) 2018-11-14
BR112017017673A2 (pt) 2018-07-17
WO2016133989A1 (en) 2016-08-25
TW201630871A (zh) 2016-09-01
IL253901A0 (en) 2017-10-31
MX2017010567A (es) 2018-03-16
MA41557A (fr) 2017-12-26
EA201791839A1 (ru) 2018-02-28
US20180036260A1 (en) 2018-02-08
CA2976229A1 (en) 2016-08-25
US10722479B2 (en) 2020-07-28
AR103728A1 (es) 2017-05-31
EP3258926A1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
JP2021100941A (ja) Ｖｍａｔ２のベンゾキノロン阻害剤
US20100120733A1 (en) Steroid modulators of glucocorticoid receptor
US10689370B2 (en) Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator
US20110206780A1 (en) Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors
US20100291151A1 (en) 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
BRPI0913457B1 (pt) Composto e composição farmacêutica
US20100087455A1 (en) Substituted xanthine compounds
US20180016244A1 (en) Deuterium-substituted oxadiazoles
US20110117214A1 (en) Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
EP3611159B1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
WO2016109359A1 (en) Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US20100113496A1 (en) Piperidine modulators of vmat2
US20100125094A1 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
US20100152283A1 (en) Tetrahydrocannabinol modulators of cannabinoid receptors
US20100075950A1 (en) Phenylpropanone modulators of dopamine receptor
US20100119622A1 (en) 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
US20100286124A1 (en) Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US10722479B2 (en) Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
US20100143287A1 (en) Trifluoromethylphenyl modulators of calcium-sensing receptor
US20100160271A1 (en) Bicyclic modulators of h1 receptors
US20100160272A1 (en) Oxepine modulators of h1 receptors and/or inhibitors of mast cell degranulation
US20100120756A1 (en) Phenothiazine modulators of h1 receptors
US20100152224A1 (en) Scopine modulators of muscarinic acetylcholine receptor
US20100137268A1 (en) Phthalazinone modulators of h1 receptors and/or ltc4 receptors
US20100087364A1 (en) Tropine modulators of 5-ht3 receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200701